In every big biotech buyout the big winners are the shareholders and every top executive at the company. And Juno Therapeutics is no exception.
Top earners garnered the most cash, starting with CEO Hans Bishop.
Bishop’s stock in the company is worth $205 million, with an additional set of vested and unvested options registering $68 million and another $8.6 million in restricted shares. That’s a $281.6 million payday, plus another two years salary — $1.3 million cash — to get through the transition. There’s also covered COBRA and $3.4 million for his golden parachute taxes.
CFO Steve Harr has a stock pile worth $56.5 million with $29 million in options and $7.4 million in restricted shares. That’s about $93 million.
Other standouts include general counsel Bernard “Barney” Cassidy, with $27 million in shares, as well as Agarwal with about $20 million worth of options after less than 10 months on the job.
One of the grand prize winners, though, is board member Robert Nelsen, who helped get the whole thing going, raised hundreds of millions of dollars and pointed Juno into the front ranks of the CAR-T leaders, never losing faith even in the dark days of their lead drug’s lethal implosion during a pivotal study.
Nelsen’s Arch Venture owns $922,479,618 worth of stock in Juno. And that’s a lot of A rounds to come.
Arch went into the Juno deal thinking big. And they won big.
Image: Hans Bishop Bloomberg via Getty Images
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription